RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

NCT04037358 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Radium-223
RADIATION: stereotactic ablative radiotherapy (SABR)

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]